In addition, terminally differentiated CD45RA (TEMRA, CD3+CD4+CD45RA+CD62L−) T helper cells were increased in patients treated with JAKis in comparison with healthy and RA controls [1.50 (0.66–3.13), 0.38 (0.14–1.55), and 0.33 (0.14–1.18), p = 0.005 and p = 0.003]. The gene discussed is SELL; the disease is rheumatoid arthritis.